Showing 1471-1480 of 1626 results for "".
- Regeneron’s Inmazeb Becomes First FDA-Approved Treatment for Ebola Virushttps://modernod.com/news/regenerons-inmazeb-becomes-first-fda-approved-treatment-for-ebola-virus/2478420/The FDA announced Wednesday that it has approved Regeneron Pharmaceuticals’ triple antibody cocktail Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn) for use in adult and paediatric patients, making it the first drug cleared in the US to treat Ebola virus infection. According to the a
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- Ocugen Receives Fourth FDA Orphan Drug Designation for Gene Therapy for the Treatment of Another Inherited Retinal Diseasehttps://modernod.com/news/ocugen-receives-fourth-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-another-inherited-retinal-disease/2478149/Ocugen announced the FDA granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and
- Ocugen Granted FDA Orphan Drug Designation for Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-rho-mutation-associated-retinal-degenerative-disease/2478081/Ocugen announced the FDA granted the third orphan drug designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the retinitis pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- Steven Sobelhttps://modernod.com/profiles/steven-sobel/L2e6ve/
- Steven Ferrucci, OD, FAAOhttps://modernod.com/profiles/steven-ferrucci-od-faao/OYAW56/
- M. Shane Swatts, ODhttps://modernod.com/profiles/m-shane-swatts-od/OWG1Y8/
- M. Nabila Gomez, OD, FAAOhttps://modernod.com/profiles/m-nabila-gomez-od-faao/Onm3b1/
- Crystal M. Brimer, OD, FAAOhttps://modernod.com/profiles/crystal-m-brimer-od-faao/Lb0N40/